<DOC>
	<DOCNO>NCT00698724</DOCNO>
	<brief_summary>To compare efficacy twice-daily topical bromfenac ( Xibrom ) ophthalmic solution alone versus twice-daily topical Xibrom prednisolone acetate 1 % three-times daily visual acuity OCT measurement .</brief_summary>
	<brief_title>Comparing Optical Coherence Tomography ( OCT ) Visual Acuity Outcomes Subjects Undergoing Cataract Surgery , Who Receive Xibrom Ophthalmic Solution Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1 % Standard Presurgical Care</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Bromfenac</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Male female least 18 year age . Expectation 20/25 best correct visual acuity ( BCVA ) postoperatively . Patients good general health devoid recognize risk factor CME . Patients systemic disease eligible ocular manifestation disease ( specifically diabetic without retinopathy ) Patients must likely provide informed consent , take study medication direct , complete study visit Only one eye treat patient may include study Any known contraindication study medication component Presence uncontrolled systemic disease Required use ocular medication study Artificial tear may use Diabetics clinically evident history retinopathy Individuals agerelated macular change , epiretinal membrane , retinovascular disease and/or macular disorder think less 20/25 surgical outcome expectation Abnormal preoperative OCT ( obtainable )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>